A Multicenter, Randomized, Double-blind, Placebo-parallel Controlled Study to Evaluate the Efficacy and Safety of Jaktinib Hydrochloride Tablets in Participants Receiving the Best Available Treatment for Severe Novel Coronavirus Pneumonia

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 03 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gecaxitinib hydrochloride (Primary)
Indications COVID-19 pneumonia
Focus Therapeutic Use
Sponsors Suzhou Zelgen Biopharmaceuticals

Most Recent Events

25 Apr 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
20 Oct 2023 Planned initiation date changed from 1 Apr 2023 to 1 Dec 2023.
22 Mar 2023 Planned initiation date changed from 1 Jan 2023 to 1 Apr 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight